Novartis, a Swiss multinational pharmaceutical company, completed the acquisition of Amblyotech, a clinical-stage digital therapeutics company. Financial terms were not disclosed. "The acquisition by Novartis provides the Amblyotech technology with the opportunity to immediately benefit from Novartis's expertise in clinical development, regulatory and commercialization to help the portfolio reach its full potential," Robert Derricotte, Amblyotech COO.